Clinical Trial Update: Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the XP-006 mRNA vaccine for relapsed/refractory B-cell non-Hodgkin lymphoma is listed as not yet recruiting, sponsored by Ru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• XP-006

Snippet

Sponsor: Ruijin Hospital | Conditions: B-cell Non-Hodgkin's Lymphoma (B-NHL) | Phase 1 | Status: NOT_YET_RECRUITING